

April 8, 2009

Cancer Snapshot

Event: American Association of Cancer Research, April 18-22, 2009



Cancer Drugs with USD +500m Peak Sales

Roche/Genentech (OTC:RHHBY, NYSE:DNA): Avastin, Rituxan, Herceptin, Tarceva, Xeloda

[Genentech: Avastin may encounter reimbursement difficulties in adjuvant CRC due to use of disease-free survival as primary endpoint in the C-08 trial](#) (**Pharmawire**)

[Genentech: Rituxan likely to see decrease in off-label use in lupus due to failed LUNAR trial, physicians say](#) (**Pharmawire**)

Novartis (NYSE:NVS): Gleevec, Femara, Tasigna

[Novartis' Tasigna and Bristol-Myers Squibb's Sprycel, in cocktail therapy, could overcome CML drug resistance, physicians say](#) (**Pharmawire**)

[Novartis: Mylan's launch at risk of generic Femara could erode Arimidex sales; recent precedent could favour a preliminary injunction](#) (**Pharmawire**)

GlaxoSmithKline (NYSE:GSK): Tykerb, Casopitant

[GSK's oral Tykerb faces reimbursement challenges in current IV treatment model, physicians say](#) (**Pharmawire**)

Merck/Schering Plough (NYSE:MRK, SGP): Gardasil, Temodar, Zolinza, Emend

[Merck's Gardasil vaccine shows limited efficacy on precancerous grade 3 cervical lesions, physicians say](#) (**Pharmawire**)

[Merck's Gardasil vaccine encounters skepticism from some physicians regarding wide-scale use, long-term safety and efficacy](#) (**Pharmawire**)

Eli Lilly (NYSE:LLY): Erbitux, Gemzar, Alimta

[Eli Lilly: Erbitux as potential first-line agent in NSCLC may limit use of second-line EGFR-inhibitors like Tarceva if patient progresses - analysis](#)

(**Pharmawire**)

[Genentech's Avastin and Lilly's Erbitux: combination Phase III SWOG trial for treatment of NSCLC faces significant hurdles - analysis](#) (**Pharmawire**)

[Eli Lilly: Erbitux unlikely to be widely adopted in NSCLC despite potential approval as mixed-results from FLEX and BMS-099 trials still linger](#) (**Pharmawire**)

[Eli Lilly and Amgen's market in colorectal cancer may be further decreased with additional patient stratification by BRAF mutation - analysis](#) (**Pharmawire**)

Pfizer/Wyeth (NYSE:PFE, WYE): Sutent, Aromasin, Camptosar, Axitinib

Sanofi-Aventis (NYSE:SNY): Taxotere, Eloxatine

AstraZeneca (NYSE:AZN): Arimidex, Casodex, Zoladex

Bristol Myers Squibb (NYSE:BMJ): Dasatinib, Ixempra, Erbitux



Unpartnered Targets

Angiochem (private): ANG1005

[AngioChem trade sale possible in 12-18 months as it seeks partner for novel brain cancer drug ANG1005 after Phase I/II data, CEO says](#) (**Pharmawire**)

ANG1005 (Angiopep-2/paclitaxel conjugate) as a promising new drug therapy for patients with malignant glioma, Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM, Hall B-F, Poster Section 38

Peregrine Pharmaceuticals (NASDAQ:PPHM): Cotara (bavituximab): Market cap USD 86m: Cash + MS USD 9m: Cash Burn 9 months

[Peregrine Pharmaceuticals seeks partner for brain cancer drug Cotara, oncology compound bavituximab; Schering Plough tops list, CEO says](#) (**Pharmawire**)

Fully human anti-phosphatidylserine antibody inhibits the growth of prostate cancer in mice, Wednesday, Apr 22, 2009, 8:00 AM -12:00 PM, Hall B-F, Poster Section 33

Micromet (NASDAQ:MITI): MT-103 (blinatumomab): Market Cap USD 155m: Cash + MS USD 14m: Cash Burn 13 months

[Micromet's blinatumomab may overcome previous failures targeting the CD-19 pathway due to proprietary antibody technology - physicians](#) (**Pharmawire**)

Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110, Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM, Hall B-F, Poster Section 12

Array BioPharma (NASDAQ:ARRY): ARRY-520: Market Cap USD 144m: Cash + MS USD 56m: Cash Burn 6 months

[Array BioPharma prefers to use partnerships as the way to raise financing, expects two deals in 2009, CEO says](#) (**Pharmawire**)

In vivo and pharmacodynamic profiling of the KSP inhibitor ARRY-520 supports potent activity in hematological cancers and drug resistant tumors, Tuesday, Apr 21, 2009, 1:00 PM - 5:00 PM, Hall B-F, Poster Section 37

Allos Therapeutics (NASDAQ:ALTH): pralatrexate: Market Cap USD 472m: Cash + MS USD 77m: Cash Burn 21 months

[Allos Therapeutics pursuing combination studies with pralatrexate, will entertain ex-US partnerships, CMO says](#) (**Pharmawire**)

Cytotoxicity of pralatrexate, a novel synthetic antifolate, in human cancer cell lines, Sunday, Apr 19, 2009, 1:00 PM - 5:00 PM, Hall B-F, Section 33

Supergen (NASDAQ:SUPG): MP-470: Market Cap USD 100m

[SuperGen will not take any compound into Phase III trials if unpartnered, out-licensing pipeline, CEO says](#) (**Pharmawire**)

MP-470, a Rad51 suppressor and multiple TK inhibitor, retards growth of primary human glioblastoma multiforme (GBM) cells and synergizes effect of Temozolomide ex vivo, Tuesday, Apr 21, 2009, 8:00 AM -12:00 PM, Hall B-F, Poster Section 36

Medigene (FRA:MDG): EndoTAG-1: Market Cap EUR 138m

[Medigene wants to wait for release of EndoTAG-1 final results before agreeing partnership or M&A deal - spokesperson](#) (**Pharmawire**)

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a diagnostic tool for early response to anti-angiogenic treatment with cationic liposomal paclitaxel (EndoTAG®-1) in patients suffering from secondary liver tumors, Sunday, Apr 19, 2009, 8:00 AM -12:00 PM, Hall B-F, Poster Section 32